Overview

Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

Status:
Completed
Trial end date:
2000-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Mitomycin
Mitomycins
Mitoxantrone
Sargramostim